Precision Medicine in Kidney Disease

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 March 2027 | Viewed by 1978

Special Issue Editors


E-Mail
Guest Editor Assistant
Nephrology and Dialysis Department, Maggiore "Nino Baglieri" Hospital, Modica, 97015 Ragusa, Italy
Interests: kidney disease; kidney transplantation; chronic renal failure; chronic kidney disease; hemodialysis; peritoneal dialysis; renal failure

Special Issue Information

Dear Colleagues,

Precision medicine is redefining the way that we approach nephrology, moving from general therapeutic strategies to individualised treatment based on genetic, molecular, and clinical profiling. The heterogeneity of kidney disease requires customised interventions that go beyond “one-size-fits-all” models.

Over the last two decades, nephrology has seen an increasing integration of biomarkers, pharmacogenomics, and systems biology into clinical practice. This shift reflects the need to optimize outcomes in complex patient populations, particularly those with chronic kidney disease, glomerular disorders, and dialysis-dependent diseases.

This Special Issue aims to explore the full potential of precision medicine in nephrology. We look forward to contributions that demonstrate how new technologies, data analysis, and individualized therapeutic targets can improve the diagnosis, risk stratification, and response to treatment of kidney disease.

We are particularly interested in studies that use multi-omics, artificial intelligence, digital health platforms, or advanced imaging to develop predictive models, personalized drug delivery systems, or innovative stratification tools for nephrology patients.

We invite original research articles and reviews that address the implementation, challenges, and future directions of precision medicine in kidney disease—from bench to bedside.

Dr. Guido Gembillo
Guest Editor

Dr. Concetto Sessa
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • chronic kidney disease
  • diabetic kidney disease
  • renal anaemia
  • renal transplant
  • dialysis
  • biomarkers
  • pharmacogenomics
  • personalized therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 454 KB  
Article
Prediction of Mortality in Hemodialysis Patients Using Inflammation- and Nutrition-Based Indices
by Umit Cakmak, Nurgul Sevimli, Suleyman Akkaya and Ozgur Merhametsiz
J. Pers. Med. 2025, 15(10), 489; https://doi.org/10.3390/jpm15100489 - 13 Oct 2025
Cited by 3 | Viewed by 1434
Abstract
Background and Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are characterized by persistent inflammation, malnutrition, and immune dysfunction, all of which contribute to poor outcomes in hemodialysis (HD) patients. The C-reactive protein albumin lymphocyte (CALLY) index has been proposed as [...] Read more.
Background and Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are characterized by persistent inflammation, malnutrition, and immune dysfunction, all of which contribute to poor outcomes in hemodialysis (HD) patients. The C-reactive protein albumin lymphocyte (CALLY) index has been proposed as a novel biomarker that integrates these mechanisms. This study aimed to evaluate the prognostic value of the CALLY index together with established markers, including the C-reactive protein-to-albumin ratio (CAR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-lymphocyte ratio (MLR) for all-cause mortality in HD patients. Materials and Methods: This retrospective cohort study was conducted on 106 patients undergoing HD. Demographic, clinical, and laboratory parameters were obtained three months after the effects of HD initiation was reviewed. Results: During a median follow-up of 24.5 months, 29 patients (27.3 percent) died. Non-survivors were significantly older (65.3 vs. 52.5 years, p < 0.001), had a higher prevalence of coronary artery disease (31 percent vs. 2.6 percent, p < 0.001), or shorter dialysis duration (14 vs. 27 months, p < 0.001). They also showed lower hemoglobin (9.2 vs. 10.1 g/dL, p = 0.007), creatinine (5.3 vs. 6.3 mg/dL, p = 0.048), and albumin levels (28 vs. 34 g/L, p = 0.001), as well as a higher MLR (0.329 vs. 0.254, p = 0.014). In multivariate analysis, age, CAR, and NLR independently predicted mortality, explaining 83.8% of the variation. ROC analysis identified age and MLR as significant predictors, with MLR showing a high negative predictive value (83.9%). The CALLY index did not demonstrate independent prognostic value. Conclusions: Age, CAR, NLR, and MLR were independent predictors of mortality in HD patients, whereas the CALLY index was not prognostic in this cohort. Among these markers, MLR may be a practical biomarker with strong negative predictive power. Larger prospective studies are needed to validate these findings. Full article
(This article belongs to the Special Issue Precision Medicine in Kidney Disease)
Show Figures

Figure 1

Back to TopTop